Paul E. Oberstein
Distinguished in Lynch Syndrome

Dr. Paul E. Oberstein

Oncology | Hematology
New York University
550 1st Ave, 
New York, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Distinguished in Lynch Syndrome
New York University
550 1st Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Paul Oberstein is an Oncologist and a Hematologist in New York, New York. Dr. Oberstein is rated as a Distinguished provider by MediFind in the treatment of Lynch Syndrome. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Stomach Cancer, and Colorectal Cancer.

His clinical research consists of co-authoring 50 peer reviewed articles and participating in 23 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in PA
Hospital Affiliations
Nyu Langone Hospitals
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
MMM Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

NEW YORK UNIVERSITY
550 1st Ave, New York, NY 10016
Other Locations
NEW YORK UNIVERSITY
240 E 38th St, New York, NY 10016
NEW YORK UNIVERSITY
111 Broadway, New York, NY 10006

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Enrollment Status: Recruiting
Publish Date: February 28, 2025
Intervention Type: Other
A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: FOLFIRINOX, Losartan, Nivolumab
Study Phase: Phase 2
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Drug
Study Drugs: Zimberelimab, Nab-Paclitaxel, Gemcitabine, AB680 CD73 Inhibitor
Study Phase: Phase 1
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Biological, Procedure, Drug
Study Drugs: Anetumab ravtansine, Gemcitabine hydrochloride, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 09, 2025
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction With the Hypomethylating Agent Azacitidine in Patients With Advanced Pancreatic Cancer After Failure of First-Line Therapy
Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction With the Hypomethylating Agent Azacitidine in Patients With Advanced Pancreatic Cancer After Failure of First-Line Therapy
Enrollment Status: Completed
Publish Date: June 17, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Azacitidine
Study Phase: Phase 2
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 1B Study to Determine the Safety and Tolerability and Confirm the Dose of Canakinumab and Spartalizumab in Combination With Nab-paclitaxel and Gemcitabine for Patients With Metastatic Pancreatic Cancer
A Phase 1B Study to Determine the Safety and Tolerability and Confirm the Dose of Canakinumab and Spartalizumab in Combination With Nab-paclitaxel and Gemcitabine for Patients With Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drugs: Canakinumab, Spartalizumab, Nab-Paclitaxel, Gemcitabine
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 3
Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Other
Study Phase: Phase 3
An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: ATP-128, BI-754091
Study Phase: Phase 1
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred
Enrollment Status: Terminated
Publish Date: November 06, 2024
Intervention Type: Drug
Study Drugs: SM-88, MPS (methoxsalen, phenytoin, sirolimus), Capecitabine, Gemcitabine, 5-FU
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study (KEYNOTE-202)
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study (KEYNOTE-202)
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drugs: BL-8040, Pembrolizumab, Chemotherapy of Onivyde
Study Phase: Phase 2
A Phase II Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
A Phase II Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Drug
Study Drugs: Lenvatinib, Pembrolizumab
Study Phase: Phase 2
A Phase II Study of Chemotherapy and Immune Checkpoint Blockade With Pembrolizumab in the Perioperative and Maintenance Treatment of Locoregional Gastric or GE Junction Adenocarcinoma.
A Phase II Study of Chemotherapy and Immune Checkpoint Blockade With Pembrolizumab in the Perioperative and Maintenance Treatment of Locoregional Gastric or GE Junction Adenocarcinoma.
Enrollment Status: Completed
Publish Date: February 15, 2024
Intervention Type: Drug
Study Drugs: Pembrolizumab, Standard of care chemotherapy regimen
Study Phase: Phase 2
A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy
A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy
Enrollment Status: Terminated
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: January 03, 2023
Intervention Type: Drug
Study Drugs: CPI 613, mFolfirinox, Folfirinox
Study Phase: Phase 3
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Drug, Procedure, Radiation
Study Drugs: mFOLFIRINOX, FOLFOX
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 20 Less Clinical Trials

50 Total Publications

Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer.
Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer.
Journal: JAMA oncology
Published: September 18, 2025
Similar Doctors
Elite in Lynch Syndrome
Dr. Zsofia K. Stadler
Hematology Oncology | Oncology
Elite in Lynch Syndrome
Dr. Zsofia K. Stadler
Hematology Oncology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
 (1.0 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Zsofia Stadler is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Stadler is rated as a Distinguished provider by MediFind in the treatment of Lynch Syndrome. Her top areas of expertise are Lynch Syndrome, Colorectal Cancer, Familial Colorectal Cancer, Colonoscopy, and Endoscopy. Dr. Stadler is currently accepting new patients.

Elite in Lynch Syndrome
Dr. Andrea Cercek
Oncology | Hematology
Elite in Lynch Syndrome
Dr. Andrea Cercek
Oncology | Hematology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
 (1.0 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrea Cercek is an Oncologist and a Hematologist in New York, New York. Dr. Cercek is rated as an Elite provider by MediFind in the treatment of Lynch Syndrome. Her top areas of expertise are Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Lynch Syndrome, Hepatectomy, and Gallbladder Removal.

Elite in Lynch Syndrome
Dr. Kenneth Offit
Oncology
Elite in Lynch Syndrome
Dr. Kenneth Offit
Oncology

Memorial Clinical Genetics Group

1275 York Ave, 
New York, NY 
 (1.7 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kenneth Offit is an Oncologist in New York, New York. Dr. Offit is rated as a Distinguished provider by MediFind in the treatment of Lynch Syndrome. His top areas of expertise are Breast Cancer, Lynch Syndrome, Ovarian Cancer, Salpingo-Oophorectomy, and Prostatectomy. Dr. Offit is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Oberstein's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile